BiotechTube

(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis

Phase 1/2Completed
0 watching 0 views this week⚡ Active
40
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pertussis

Conditions

Pertussis, Tetanus, Diphtheria

Trial Timeline

Sep 1, 2012 → May 1, 2013

NCT ID
NCT01689324

About (ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis

(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis is a phase 1/2 stage product being developed by Sanofi for Pertussis. The current trial status is completed. This product is registered under clinical trial identifier NCT01689324. Target conditions include Pertussis, Tetanus, Diphtheria.

Hype Score Breakdown

Clinical
13
Activity
8
Company
9
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT01689324Phase 1/2Completed

Competing Products

16 competing products in Pertussis

See all competitors
ProductCompanyStageHype Score
Adacel®SanofiApproved
84
aP booster + TdaP booster + Licensed TdaP booster (Boostrix®)NovartisPhase 1
33
Boostrix + Placebo (Saline)NovartisApproved
85
Acellular pertussis vaccine + Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) + Licensed TdaP booster vaccine + Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)NovartisPhase 1
33
Tetanus Toxoid, acellular pertussis, diphtheria toxoidSanofiPre-clinical
22
ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed + BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis AdsorbedSanofiApproved
84
COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)SanofiApproved
84
DT5aP-IPV-Hib 5-component Pertussis vaccine + Infanrix® -IPV+HibSanofiPhase 3
76
Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV + Hepatitis B vaccineSanofiPhase 2
51
DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus) + DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b) + Inactivated Poliomyelitis Vaccine + Poliomyelitis Vaccine bivalent types 1 and 3 + Human Rotavirus, live attenuated + Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)SanofiPhase 3
76
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis VaccineSanofiApproved
84
Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®) + Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)SanofiApproved
84
Pentacel® (DTaP-IPV/Hib) + Other Pertussis VaccinesSanofiPre-clinical
22
DTaP-IPV combined vaccine + DTaP vaccineSanofiPhase 3
76
ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed + DECAVAC®: Tetanus and Diphtheria Toxoids AdsorbedSanofiApproved
84
Tetanus and diphtheria toxoids and acellular pertussisSanofiPre-clinical
22

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84